bortezomib
takeda
['dlbcl', 'borte', ' abc,(- abcsg)', 'bortezomib']
impressive long-term results of phase iii remodl-b trial highlight importance of testing targeted agents using molecular features (i.e gep) for dlbcl. addition of bortezomib for abc 5-year pfs 54% vs 69%, os 67% vs 80% (p=0.032.) #ash2022 #clecliniccancer 
Director, Lymphoid Malignancies. @ClevelandClinic Taussig #Cancer Center, #lymphoma, #CLL, #ChronicLymphocyticLeukemia, #Tcellrx, #CARTcell